GLAUCARUBIN

First approved in 1955

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H36O10
Molecular Weight	496.5473
Optical Activity	UNSPECIFIED
Defined Stereocenters	13 / 13
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@](C)(O)C(=O)O[C@@H]1[C@H]2[C@@H](C)[C@@H](O)[C@]3(O)OC[C@@]24[C@H]3[C@@]5(C)[C@H](O)[C@@H](O)C=C(C)[C@@H]5C[C@H]4OC1=O

InChI

InChIKey=LZKVXMYVBSNXER-YZPKDWIXSA-N

InChI=1S/C25H36O10/c1-6-22(4,31)21(30)35-16-15-11(3)17(27)25(32)20-23(5)12(10(2)7-13(26)18(23)28)8-14(34-19(16)29)24(15,20)9-33-25/h7,11-18,20,26-28,31-32H,6,8-9H2,1-5H3/t11-,12+,13+,14-,15-,16-,17-,18-,20-,22+,23-,24+,25+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C25H36O10
Molecular Weight	496.5473
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	13 / 13
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/mesh/68005900 | https://www.ncbi.nlm.nih.gov/pubmed/13292450 | http://www.hmdb.ca/metabolites/HMDB0035626

GLAUCARUBIN is a quassinoid isolated from Simaruba glauca, a tropical shrub. It is used as an antiamebic agent.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
intestinal amebiasis 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13942344	Primary		Not Provided 511	Glarubin Approved Use Unknown

Doses

Dose	Population	Adverse events
280 mg 1 times / day multiple, oral Studied dose Dose: 280 mg, 1 times / day Route: oral Route: multiple Dose: 280 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/13292450	unhealthy, 63 years Health Status: unhealthy Age Group: 63 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/13292450	Sources: https://pubmed.ncbi.nlm.nih.gov/13292450

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L9BO7
ABI Chem	AC1MOJ8O
Alfa Chemistry	1448-23-3	https://www.alfa-chemistry.com/cas_1448-23-3.htm
ChemIDplus	1448233	https://chem.nlm.nih.gov/chemidplus/id/0001448233
Chemieliva Pharmaceutical Co., Ltd	PBCM1188071
ChemMol	99040826	http://www.chemmol.com/chemmol/99040826.html
Compound Cloud	441794
NovoSeek	441794
Smolecule	S528933	http://www.smolecule.com/products/s528933
THE BioTek	bt-269521	https://www.thebiotek.com/product/inhibitors/bt-269521
ZINC	ZINC000008221332	http://zinc15.docking.org/substances/ZINC000008221332

PubMed

Title	Date	PubMed
The use of glaucarubin (a crystalline glycoside isolated from Simarouba glauca) in the treatment of human colonic amebiasis.	1956-05	13327185
Clinical trial of glaucarubin in treatment of amebiasis.	1956-03	13292450

Sample Use Guides

In Vivo Use Guide

Treatment by mouth for 10 days with daily doses of 5 mg/kg (maximum daily dose of 300 mg).

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:45:58 GMT 2025` Edited by `admin` on `Mon Mar 31 17:45:58 GMT 2025`
Record UNII	EH6H7VS52J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NSC-14975

Preferred Name

English

GLAUCARUBIN

Common Name

English

PICRAS-3-EN-16-ONE, 11,20-EPOXY-1,2,11,12-TETRAHYDROXY-15-(2-HYDROXY-2-METHYL-1-OXOBUTOXY)-, (1.BETA.,2.ALPHA.,11.BETA.,12.ALPHA.,15.BETA.(S))-

Systematic Name

English

GLAUCARUBIN [MI]

Common Name

English

GLAUMEBA

Brand Name

English

Code System Code Type Description

CAS

1448-23-3